Perspectives in weight control in diabetes - BI 456906 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37330144/
Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved treatments for Type 2 diabetes mellitus, with liraglutide and semaglutide also approved for the treatment of obesity. The natural gut hormone oxyntomodulin is...
Conclusions/Relevance: These data highlight the potential of dual GCGR/GLP-1R agonism for reducing glycated haemoglobin and body weight in patients with Type 2 diabetes mellitus, and for greater therapeutic efficacy compared with GLP-1R agonism alone.
Share
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37313232/
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the management of type 2 diabetes and obesity. Unlike several classes of antidiabetic medications that contribute to weight gain, GLP-1RAs not...
Conclusions/Relevance: The outcomes of paediatric trials evaluating liraglutide, exenatide, semaglutide and dulaglutide in paediatric type 2 diabetes and obesity will be closely examined, including differences compared with adult studies. Finally, potential barriers and strategies to expanding GLP-1RA access in adolescents will be discussed....
Share
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis - International Journal of Obesity
Source : https://www.nature.com/articles/s41366-023-01321-5
Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess...
Conclusion: Tirzepatide has significant potential as a weight loss drug in patients with overweight and obesity, with little increase in AEs compared to other weight loss drugs. With its ability to concurrently target multiple aspects of metabolic syndrome, it should be considered as the next helm of weight loss therapies.
Share
Relevance: Can behavioral interventions designed to treat childhood obesity be delivered in pediatric primary care settings?
Share
Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37278394/
Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity-related complications, and...
Conclusions: The evidence discussed in this article demonstrates that GLP‐1 RAs should be strongly considered as an option for use in clinical practice for the treatment of obesity and reduction of CVD risk in people with T2D.
Share